|
3/2024
vol. 10
Original paper
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
Aleksandra Berkan-Kawińska
1
,
Magdalena Tudrujek-Zdunek
5
,
Anna Parfieniuk-Kowerda
9
,
- Department of Infectious Diseases and Hepatology, Medical University of Lodz, Łódź, Poland
- Hospital for Infectious Diseases, Warsaw Medical University, Warsaw, Poland
- Clinical Department of Infectious Diseases, Medical University of Silesia, Chorzów, Poland
- Department of Infectious and Tropical Diseases, Collegium Medicum, Jagiellonian University, Kraków, Poland
- Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland
- Department of Infectious Diseases, Pomeranian Center of Infectious Diseases, Medical University of Gdansk, Gdańsk, Poland
- Department of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland
- Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University, Szczecin, Poland
- Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
Clin Exp HEPATOL 2024; 10, 3: 165-169
Online publish date: 2024/07/29
Get citation
PlumX metrics:
1. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 797-808. 2.
Nishikawa K, Kimura M, Imamura J, Kimura K. Prevalence of hepatitis C virus infection among men who have sex with men with human immunodeficiency virus-1 infection between 2010 and 2020 in Japan: A single-center retrospective cohort study. J Infect Chemother 2023; 29: 263-268. 3.
Leszczyszyn-Pynka M, Ciejak P, Maciejewska K, et al. Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland. Arch Med Sci 2018; 14: 554-559. 4.
de Lédinghen V, Barreiro P, Foucher J, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat 2008; 15: 427-433. 5.
Sax PE, Arribas JR, Orkin C, et al.; GS-US-380-1489 and GS-US-380-1490 study investigators. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine 2023; 59: 101991. 6.
Biktarvy Prescribing Information, Gilead Sciences Inc., March 2021. 7.
Maviret Summary of Product Characteristics, AbbVie Ltd., June 2021. 8.
Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: The EXPEDITION-2 study. Clin Infect Dis 2018; 67: 1010-1017. 9.
Cornberg M, Ahumada A, Aghemo A, et al.; CREST Study Group. Safety and effectiveness using 8 weeks of glecaprevir/pibrentasvir in HCV-infected treatment-naïve patients with compensated cirrhosis: The CREST study. Adv Ther 2022; 39: 3146-3158. 10.
Huang CF, Kuo HT, Chang TS, et al. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Sci Rep 2021; 11: 23473. 11.
Gonzalez-Serna A, Corma-Gomez A, Tellez F, et al. Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice. J Antimicrob Chemother 2023; 78: 2591-2596. 12.
Liverpool Hep Interactions: https://www.hep-druginteractions.org/checker (access: 15 May 2024). 13.
Maviret Summary of Product Characteristics, AbbVie Ltd., March 2023 14.
Bhattacharya D, Aronsohn A, Price J, Lo Re V; AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2023: ciad319. 15.
European Association for the Study of the Liver. Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol 2020; 73: 1170-1218. 16.
Amariles P, Rivera-Cadavid M, Ceballos M. Clinical relevance of drug interactions in people living with human immunodeficiency virus on antiretroviral therapy-update 2022: Systematic review. Pharmaceutics 2023; 15: 2488. 17.
Yaras S, Demir M, Barutcu S, et al. The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort. Hepatol Forum 2023; 4: 92-96. 18.
Liu CH, Liu CJ, Hung CC, et al. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. Liver Int 2020; 40: 758-768.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
|
|
